editor
sever
acut
respiratori
syndrom
sar
emerg
diseas
caus
novel
coronaviru
sarscov
caus
worldwid
outbreak
result
case
countri
fatal
sarscov
belong
coronavirida
genu
hepat
c
viru
hcv
belong
flavivirida
genu
two
differ
virus
posit
singl
strain
rna
virus
ssrna
similar
characterist
immun
respons
might
offer
insight
treatment
sar
cinatl
et
al
first
report
interferon
beta
could
inhibit
sarscov
replic
vitro
cultur
similar
result
confirm
hensley
et
al
furthermor
form
interferon
interferonalpha
gamma
also
antisar
effect
vitro
studi
loutfi
et
al
report
potenti
benefit
interferon
plu
corticosteroid
sar
treatment
found
treatment
group
seem
reduc
diseaseassoci
impair
oxygen
satur
rapid
resolut
radiograph
lung
abnorm
lower
level
creatin
kinas
zhao
et
al
also
report
sar
patient
randomli
receiv
interferon
alpha
tend
shortest
admiss
day
time
need
improv
dyspnea
time
improv
chest
xray
film
treatment
regimen
ribavirin
alon
efficaci
vitro
antisarscov
test
zhao
random
trial
although
suggest
clinic
valu
cinatl
colleagu
test
certain
potenti
antisarscov
drug
includ
ribavirin
pyrazofurin
mycophenol
acid
glycyrrhizin
show
glycyrrhizin
best
potenc
inhibit
replic
sarscov
result
suggest
interferon
alpha
glycyrrhizin
could
benefici
sar
treatment
similarli
interferon
alpha
glycyrrhizin
also
effect
treat
hcv
infect
glycyrrhizin
lower
serum
alt
treatment
reduc
inflamm
hcv
infect
prevent
develop
hepatoma
glycyrrhizin
fewer
sideeffect
seem
effect
ribavirin
treat
hcv
infect
taken
togeth
result
suggest
sarscov
hcv
might
similar
immunopathogenesi
patient
chronic
hcv
infect
tend
domin
previou
studi
also
found
wang
et
al
predomin
cytokin
profil
increas
earli
stage
sar
infect
within
day
symptom
follow
predomin
cytokin
profil
elev
late
stage
week
symptom
suggest
host
immun
respons
earli
sar
infect
might
favor
viral
replic
week
sarscov
infect
host
immun
respons
induc
specif
immun
viru
clearanc
immunemedi
damag
base
skew
immun
respons
therefor
postul
use
interferon
alpha
earli
stage
sar
infect
deviat
predomin
reaction
reaction
hold
back
corticosteroid
appear
late
exacerb
show
augment
respons
anoth
similar
hcv
sarscov
infect
relat
elev
blood
level
polyak
et
al
report
chronic
hcv
infect
elev
level
associ
resist
interferon
therapi
one
possibl
mechan
might
relat
activ
map
kinas
associ
elev
level
resist
interferon
therapi
recent
shown
sar
infect
associ
mild
elev
conjunct
activ
cell
prove
relationship
activationrel
interferon
resist
sarscovor
hcvrelat
immun
respons
deserv
investig
editor
search
antimitochondri
antibodi
ama
sera
women
serologicallyproven
chlamydia
pneumonia
infect
match
control
indirectli
confirm
recent
suggest
role
bacterium
induct
primari
biliari
cirrhosi
pbc
use
sensit
methodolog
ama
determin
none
investig
sera
found
posit
ama
etiopathogenesi
primari
biliari
cirrhosi
pbc
immunemedi
biliari
diseas
still
unknown
autoantibodi
direct
ama
detect
patient
pbc
appear
highli
specif
diseas
clone
express
identif
major
bcell
epitop
greatli
facilit
specif
sensit
detect
ama
propos
infecti
agent
environment
factor
bacteria
virus
xenobiot
might
contribut
breakdown
toler
lead
autoimmun
pbc
molecular
mimicri
specif
exogen
protein
might
induc
crossreact
autoimmun
respons
host
protein
might
involv
interestingli
abdulkarim
et
al
recent
found
c
pneumonia
antigen
liver
sampl
patient
pbc
control
thu
suggest
role
bacterium
pathogenesi
pbc
howev
data
could
confirm
other
use
sensit
polymeras
chain
reaction
pcr
base
method
base
hypothesi
c
pneumonia
might
major
extern
trigger
pathogenesi
pbc
sought
ama
seri
women
welldefin
chronic
c
pneumonia
infect
diagnos
posit
nest
touchdown
pcr
peripher
blood
mononuclear
cell
posit
microimmunofluoresc
antibodi
test
igg
igg
iga
note
c
pneumonia
seropreval
middleag
gener
popul
known
sera
women
c
pneumonia
chronic
infect
mean
age
sd
agematch
healthi
women
mean
age
sd
test
ama
subject
italian
descent
present
normal
valu
serum
alkalin
phosphatas
time
enrol
latter
featur
ascertain
order
attempt
identif
pbc
case
earli
stage
women
c
pneumonia
infect
posit
activ
infect
pcr
present
titer
specif
igg
igm
iga
respect
sought
antibodi
three
major
pbcspecif
mitochondri
epitop
use
elisa
tripleexpress
hybrid
clone
previous
describ
briefli
amareact
immunodomin
epitop
within
three
distinct
lipoyl
domain
human
pyruv
dehydrogenas
complex
bovin
branchedchain
alphaketoacid
dehydrogenas
rat
oxoglutar
dehydrogenas
complex
clone
coexpress
plasmid
vector
pharmarcia
alameda
ca
usa
use
antigen
none
investig
sera
patient
c
pneumonia
infect
control
posit
ama
accordingli
use
indirect
approach
assess
role
c
pneumonia
pbc
unabl
support
involv
bacterium
induct
diseas
possibl
reason
neg
find
could
number
patient
c
pneumonia
studi
might
small
also
suggest
analysi
larg
number
pbc
sera
differ
ama
pattern
sign
c
pneumonia
infect
pursu
howev
base
consider
data
believ
etiopathogenesi
pbc
remain
unknown
search
respons
genet
environment
factor
continu
editor
ceruloplasmin
play
import
role
iron
transport
major
ferroxidas
genet
defect
involv
ceruloplasmin
synthesi
caus
sever
iron
overload
liver
brain
introduct
penicillamin
provid
signific
advanc
treatment
wilson
diseas
trientin
safer
less
potent
copper
chelat
agent
avail
patient
intoler
penicillamin
penicillamin
trientin
administr
might
reduc
patient
level
intern
bioavail
copper
therebi
lead
impair
iron
transport
previou
studi
found
penicillamin
reduc
serum
ceruloplasmin
level
caus
iron
accumul
liver
present
letter
report
two
male
patient
wilson
diseas
treat
use
trientin
phlebotomi
one
patient
develop
myasthenia
gravi
age
year
compound
heterozyg
gene
neg
hfe
gene
liver
histolog
show
chronic
hepat
histochem
iron
deposit
serum
ferritin
concentr
ngml
also
serum
ceruloplasmin
ferroxidas
level
low
mgdl
u
l
respect
one
month
discontinu
penicillamin
treatment
trientin
hydrochlorid
initi
mgday
patient
businessman
present
intent
hand
tremor
result
liver
histolog
regen
nodul
posit
copper
andor
iron
grain
suggest
cirrhosi
compound
heterozyg
gene
free
mutat
hfe
gene
trientin
hydrochlorid
mgday
reduc
serum
ceruloplasmin
protein
mgdl
within
month
liver
specimen
taken
year
treatment
still
posit
histochem
iron
serum
ferritin
ngml
serum
ceruloplasmin
ngml
wherea
serum
ferroxidas
activ
low
ul
phlebotomi
trientin
treatment
carri
obtain
written
inform
consent
patient
endpoint
serum
ferritin
concentr
ngml
hemoglobin
concentr
gdl
shown
figur
postphlebotomi
anemia
develop
patient
serum
ferritin
level
ngml
respect
compar
patient
chronic
hepat
c
endpoint
high
suggest
intoler
iron
remov
therapi
ferroxidas
defici
result
hypoceruloplasminemia
might
specif
mechan
involv
iron
deposit
associ
impair
iron
transport
caus
wilson
diseas
hypothesi
support
observ
iron
remov
phlebotomi
insuffici
patient
aceruloplasminemia
chelat
therapi
use
penicillamin
trientin
might
result
effect
excret
toxic
copper
also
inhibit
intern
bioavail
copper
iron
overload
sideeffect
use
chelat
discontinu
drug
might
recommend
phlebotomi
enough
control
ironinduc
oxid
stress
futur
effect
copper
chelat
iron
metabol
studi
use
larger
number
patient
upper
endoscopi
show
cm
dark
red
color
intralumin
polypoid
mass
mimick
hemangioma
stromal
tumor
biopsi
could
carri
suspicion
hemangioma
neck
thorax
magnet
reson
imag
mri
show
extern
compress
esophagu
caus
mm
solid
mass
upper
part
thorax
mass
extend
cranial
well
arrang
homogen
intens
two
nodul
mm
diamet
nodul
thought
origin
thyroid
gland
also
involv
retrostern
part
mediastenium
nodul
caus
remark
compress
esophag
lumen
fig
b
first
patient
thought
esophag
hemangioma
howev
mri
imag
point
thyroid
nodul
thyroid
carcinoma
could
rule
activ
thyroid
scintigraphi
patient
diagnos
thyroid
carcinoma
total
thyroidectomi
segment
resect
esophag
metastasi
carri
histopatholog
examin
show
hurthl
cell
carcinoma
thyroid
nodul
resect
materi
esophagu
patient
follow
month
outpati
clinic
asymptomat
normal
esophagographi
local
advanc
thyroid
carcinoma
involv
esophagu
origin
direct
invas
tumor
usual
confin
musculari
without
extens
submucosa
mucosa
layer
patient
complain
dysphagia
odynophagia
result
direct
invas
esophagu
extrins
compress
associ
laryngotrach
invas
patient
present
studi
dysphagia
odynophagia
hematemesi
first
thought
esophag
hemangioma
left
liver
lobectomi
result
giant
hemangioma
attribut
thyroid
carcinoma
recurr
howev
surgic
resect
patholog
examin
show
hurthl
cell
carcinoma
esophag
involv
local
advanc
thyroid
carcinoma
hurthl
cell
carcinoma
shave
resect
en
bloc
resect
segment
resect
esophagectomi
carri
surgic
treatment
appli
extens
involv
palli
dilat
stent
placement
might
help
symptomat
patient
present
patient
total
thyroidectomi
segment
esophag
resect
carri
metastat
tumor
upper
gastrointestin
tract
especi
upper
part
esophagu
rel
rare
esophag
metastasi
found
neck
head
tumor
malign
melanoma
lung
breast
cancer
must
consid
addit
hepatocellular
carcinoma
osteogen
sarcoma
renal
cell
carcinoma
germ
cell
tumor
prostat
cancer
metastat
tumor
esophagu
publish
case
report
conclus
metastat
cancer
esophagu
rare
occur
diagnosi
consid
patient
dysphagia
odynophagia
alarm
symptom
histori
previou
primari
cancer
murat
akyildiz
omer
ozutemiz
fulya
gunsar
sinan
akay
ahmet
aydin
nevra
elma
yesim
ertan
mahir
akyildiz
tankut
ilter
ege
univers
medic
school
depart
gastroenterolog
radiolog
patholog
gener
surgeri
bornova
izmir
turkey
